Patients Coming Off Weight-Loss Medications Regain Weight at a Quadrupled Rate Compared to People Using Diet and Exercise

New research indicates that individuals who stop using blockbuster weight-loss injections like Mounjaro or Wegovy tend to recover lost weight much more quickly than those who halt conventional diet and exercise programs.

Findings released in a major health publication shows that while obese individuals can lose about a fifth of their total mass while on the medication, the mass comes back at an estimated rate of nearly a kilo each month after stopping.

"Users using such drugs should be cognizant of the risk of quick weight regain when the therapy concludes," stated expert Dr. Susan Jebb.

That rate of regain suggests a return to starting mass in about a year and a half.

Weighing Treatments

The analysis, which reviewed dozens of studies involving thousands of patients, compared the effects of the injectable medications with older methods.

Scientists emphasize that individuals who lose weight through diet and exercise generally have a slower weight regain—around 0.1 kg a month—after stopping.

The Reason for the Rapid Rebound

Experts propose the mechanism of the injections accounts for the heightened regain.

These medications copy a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.

"Artificially providing the hormone concentrations several times higher than the body's typical production might result in the system to generate a reduced amount of its endogenous hormone, and could diminish sensitivity to its actions," said Dr. Adam Collins, a dietetics researcher.

"Withdrawal of this medication results in hunger is unsuppressed, making excessive eating much more probable."

An Ongoing Condition?

The NHS suggest the injections for individuals with obesity-related medical conditions, alongside recommended diet and exercise modifications.

A number of clinicians contend that, given the high risk of relapse, the treatment is often ongoing.

This opinion is reinforced by drug manufacturers, who say that the results "emphasize the long-term nature of obesity," similar to managing conditions like diabetes.

User Accounts

Users who have stopped the jabs explain a intense return of cravings.

"I experienced something activating and you become ravenous," said a patient.

This challenge is worsened if patients have not adopted lasting lifestyle or habit changes during therapy.

Significant Use

Survey data indicate that millions of adults in the UK have used weight-loss jabs in the last 12 months, with interest continuing to grow.

• Adoption is more common among females compared to men.
• The middle-aged age group shows the highest level of interest.
• Many access the drugs through private healthcare rather than the NHS.

In conclusion, clinicians stress that while GLP-1 drugs are potent agents for weight loss, they are not a standalone cure and maintained weight loss hinges on combined lifestyle support.